Regentis Biomaterials Ltd. logo

Regentis Biomaterials Ltd.

RGNT

AMEXHealthcareMedical - Instruments & Supplies

Previous close

$2.10

+$0.04 · +1.94%

Aug 21, 4:00 PM ET

RGNT company overview

Regular session · ET · Market data may be delayed.

Company profile

Company website

Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
IL
CEO
Ehud Geller
Listed since
Dec 4, 2025
Employees
10

Market position

Day range

Current $2.10

52-week range

Current $2.10

Open
$2.05
Previous close
$2.06
Volume
37.13K
0.01× average
Average volume
5.4M
Average daily volume
Market cap
14.75M USD
Beta
-0.69
Market reference 1
50-day average
$2.8998
-27.58% below average
200-day average
$3.8404
-45.32% below average

RGNT peers

Continue in GoAI

Research RGNT

research.disclaimer